U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07180927) titled 'DLL3 CAR-T Therapy Targeting Brain Tumors' on Sept. 12.
Brief Summary: The purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic pontine or midline gliomas (DIPG or DMG). Another goal of the study is to learn more about the function of the anti-DLL3 CAR-T cells and their persistency in patients.
Study Start Date: Sept. 10
Study Type: INTERVENTIONAL
Condition:
Glioblastoma of Cerebellum
Intervention:
BIOLOGICAL: 4SCAR DLL3 T cells
Infusion of 4SCAR DLL3 T cells ...